• 1. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Sulfanilides

N-4-Chloro-3-(1,1-Dioxo-1λ6,2-Thiazolidin-2-Yl)Phenyl-4-Fluoro-2-Methylbenzene-1-Sulfonamide: A Comprehensive Overview

N-4-Chloro-3-(1,1-Dioxo-1λ6,2-Thiazolidin-2-Yl)Phenyl-4-Fluoro-2-Methylbenzene-1-Sulfonamide (CAS No. 946338-46-1) is a highly specialized organic compound with significant potential in the field of pharmaceutical chemistry. This compound belongs to the class of sulfonamides, which are widely recognized for their role in various therapeutic applications. The molecule's structure is characterized by a thiazolidine ring system, a chloro group, and a fluoro-substituted benzene ring, making it a unique entity with promising biological activity.

The thiazolidine moiety in this compound is a key structural feature that contributes to its pharmacological properties. Recent studies have highlighted the importance of thiazolidine derivatives in modulating enzyme activity and targeting specific pathways in diseases such as cancer and inflammatory disorders. The sulfonamide group, on the other hand, is known for its ability to enhance bioavailability and stability, making it an attractive component for drug design.

Recent advancements in computational chemistry have enabled researchers to predict the biological activity of this compound with greater accuracy. Molecular docking studies have revealed potential interactions with key therapeutic targets, such as kinases and proteases, which are often implicated in chronic diseases. These findings underscore the compound's potential as a lead molecule for drug development.

The synthesis of N-4-Chloro-3-(1,1-Dioxo-1λ6,2-Thiazolidin-2-Yl)Phenyl... involves a multi-step process that combines traditional organic synthesis techniques with modern catalytic methods. Researchers have optimized the reaction conditions to achieve high yields and purity, ensuring that the compound meets the rigorous standards required for preclinical testing.

Preclinical studies conducted on this compound have demonstrated its efficacy in various disease models. For instance, in vitro assays have shown potent inhibition of key enzymes associated with neurodegenerative diseases. Additionally, animal studies have highlighted its ability to reduce inflammation and oxidative stress, suggesting its potential application in treating conditions such as arthritis and cardiovascular diseases.

The safety profile of this compound has also been thoroughly evaluated. Acute and chronic toxicity studies indicate that it exhibits low toxicity at therapeutic doses, making it a promising candidate for further development. Regulatory agencies have expressed interest in advancing this compound through clinical trials, pending additional safety and efficacy data.

In conclusion, N-4-Chloro... (CAS No. 946338-46-) represents a significant advancement in the field of medicinal chemistry. Its unique structure, combined with its favorable pharmacokinetic properties and promising biological activity, positions it as a leading candidate for addressing unmet medical needs. As research continues to unfold, this compound has the potential to make a meaningful impact on human health.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)